Celerion Holdings, Inc.

Celerion is a global contract research organization specializing in early-phase clinical research, clinical pharmacology, bioanalysis, and translational medicine services for pharmaceutical and biotechnology companies developing new investigational drugs. The company provides comprehensive services including first-in-human dose escalation studies, safety and tolerability assessments, pharmacokinetic and pharmacodynamic evaluations, drug-drug interactions, cardiac safety studies, bioequivalence and bioavailability studies, metabolism and excretion programs, clinical trial design and execution, patient recruitment and site management, bioanalytical testing, and data management and regulatory support services. Celerion operates a global network of clinical research facilities offering approximately 650 beds and serving more than 200 different clients annually across pharmaceutical and biotechnology companies. The company's facilities and laboratories span North America, Europe, and Asia, with locations in Lincoln, Nebraska (corporate headquarters and primary clinical research facility), Phoenix, Arizona, Belfast, Northern Ireland, Zurich, Switzerland, Montreal, Quebec, Berlin, Vienna, and Seoul, South Korea. The company traces its origins to Harris Laboratories founded in 1933 for agricultural testing, transitioning to clinical research in 1969, operating as MDS Harris following acquisition by MDS Inc., and becoming Celerion in 2010 through acquisition of early-stage development operations of MDS Pharma Services. Celerion was founded in 2010 and is headquartered in Lincoln, Nebraska, United States.